Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3452W HIGH $200.00
Volume
6.91 M
Value Traded
37.87 K
Short % Float
7.45%
Days to Cover
1.0
+40.19%Week
-25.09%1 Month
-29.12%3 Month
-90.77%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.57 M
EPS (TTM)
-2.33
P/E Ratio
-
Ent. Value
-3.38 M
Total Shares
4.38 M
Float Shares
5.23 M
Insiders
0.25%
Institutions
5.52%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ONCO Catalyst Timeline
Dated clinical, regulatory and corporate events for Onconetix, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Onconetix, Inc.
138Total events
7Upcoming
48Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Product LaunchEchoPost-Market
Realbotix launches Echo humanoid robot platform (Tabletop and Full Body models)
▲Partnership / LicenseCorporate
Onconetix makes additional $500,000 advance to Realbotix LLC under Grid Note
▲Partnership / LicenseCorporate
Onconetix provides up to $5,000,000 strategic bridge financing facility to Realbotix LLC
▲Partnership / LicenseCorporate
Realbotix secures agreement for humanoid robot appearance on Emmy-winning streaming series
▲Partnership / LicenseCorporate
Realbotix partnership with Bloom Procurement Services to launch UK pilot
▲PublicationProclarixPresentation
Publication in BMC Cancer demonstrating Proclarix performance in reducing overdiagnosis and unnecessary biopsies
prostate cancersource ↗
▲Product LaunchPost-Market
Realbotix delivers first Vinci-equipped humanoid robot to Ericsson
◆Management ChangeCorporate
Sammy Dorf appointed to Board of Directors and Audit Committee effective March 19, 2026
▲AcquisitionCorporate
Onconetix entered definitive share exchange agreement to acquire 100% of Realbotix LLC in all-stock transaction
▲Partnership / LicenseCorporate
Onconetix enters Share Exchange Agreement to acquire Realbotix LLC in all-stock transaction
▲Trial InitiationProclarixTrial
Initiation of PRIME study, a multi-center clinical validation study in collaboration with Labcorp
prostate cancersource ↗
▲Partnership / LicenseProclarixCorporate
Collaboration with Labcorp for PRIME study and U.S. market as lab developed test
prostate cancersource ↗
▲Other Regulator MilestoneProclarixEx-US Regulatory
European commercial expansion: UK patient organization offering Proclarix in real-world screening initiative
prostate cancersource ↗
▲Product LaunchOmlontiPost-Market
Commercial launch of Omlonti to commence in coming weeks
ophthalmicsource ↗
▼Partnership / LicenseCorporate
Mutual termination of merger agreement between Onconetix and Ocuvex
▲Partnership / LicenseCorporate
Proteomedix licenses manufacturing IP to Immunovia for PancreaSure test
pancreatic cancersource ↗
▼Equity OfferingCorporate
Private placement of Series D Preferred Stock and warrants for $12.9 million
◆Timing GuidancePresentation
Expected demonstration of compliance with Bid Price Listing Rule
▼Reverse Stock SplitCorporate
1-for-85 reverse stock split approved by stockholders and board, effective June 13, 2025
◆Quarterly UpdateCorporate
Nasdaq Hearings Panel hearing scheduled for minimum bid price non-compliance
▼Quarterly UpdateCorporate
Received Staff delisting letter from Nasdaq for failure to file Form 10-Q
▼Quarterly UpdateCorporate
Received Staff delisting letter from Nasdaq for failure to file Annual Report on Form 10-K
▼Quarterly UpdateCorporate
Received prior Staff delisting letter for non-compliance with Minimum Bid Price Rule
▼Quarterly UpdateCorporate
Nasdaq issued notice of closing bid price $0.10 or less for ten consecutive trading days
◆Oral PresentationProclarixPresentation
Presentation at 2025 EAU congress: Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer
prostate cancersource ↗
◆AbstractProclarixPresentation
Abstract accepted for presentation at 2025 EAU congress
prostate cancersource ↗
▼Equity OfferingCorporate
Private placement of Series C Preferred Stock and warrants for $2.0 million gross proceeds
◆ATM ProgramCorporate
Established $25 million equity line of credit via Common Stock Purchase Agreement
◆Reverse Stock SplitCorporate
1-for-40 reverse stock split approved by Board, effective September 24, 2024
Past FDA Catalysts and PDUFA Decisions
How ONCO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-12-09 | Entadfi (finasteride) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ONCO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Proclarix | prostate cancer diagnosis | 2025-03-24 | sensitivity of 96%; specificity significantly higher (p<0.001) compared to both %fPSA and ERSPC risk calculator; negative Proclarix test resulted in a probability of 5% or less for clinically significant cancer; avoided most biopsies (22%); missing the least significant cancers (3 out of 101 patients)Read More | Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohortRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HRT FINANCIAL LP10% Owner | Sell | -49,710 33,649 held | $0.69 | 04/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ONCO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ONCO for Q2 2026. | ||||
ONCO Institutional Ownership Trends
ONCO Short Interest
Shares sold short, counted twice a month.
7.45%
Short % of Float
of tradable shares sold short
389.9K
Shares Sold Short
-20.4% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
4.8M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ONCO ranks across every disease it competes in
Competitive Position is a premium feature
See how ONCO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialONCO News
-ONCO
Oct 27, 2026▲ +18.9%on this news· ran to +50% by day 1
Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
Onconetix announced the launch of Realbotix's Echo humanoid robot line, featuring a Tabletop model priced at $11,950 and a Full Body model at $59,950. The first production run will consist of 250 units, with delivery expected in 2027. This development aligns with Onconetix's pending acquisition of Realbotix LLC, which is anticipated to enhance its market position.
Read more →-ONCO
Oct 26, 2026▲ +18.9%on this news· ran to +50% by day 1shared move
Onconetix Announces Reverse Stock Split
Onconetix approved a one-for-ten reverse stock split effective November 6, 2026. The move reduces outstanding shares from approximately 5,886,774 to 588,677. Stockholders receive cash for fractional shares instead of new stock. The Nasdaq symbol remains ONCO with unchanged authorized share counts.
Read more →-ONCO
Oct 23, 2026Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
Onconetix, Inc. announced an additional $500,000 advance to Realbotix LLC, increasing total funding to $3,000,000 under a strategic bridge financing facility. This funding supports Realbotix's growth initiatives as Onconetix moves forward with its pending acquisition. The acquisition is subject to shareholder and regulatory approvals.
Read more →-ONCO
Sep 24, 2026▲ +7.4%on this news· ran to +21% by day 1
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
SRX Global Inc. has updated shareholders on the liquidation of its investments in Vistagen Therapeutics and Greenland Mines. The company has also announced a new investment in Onconetix, which is set to acquire Realbotix LLC. This move reflects SRX's strategy to focus on high-conviction investments and innovative technologies.
Read more →-ONCO
Sep 14, 2026▼ -15.7%on this news
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
Onconetix has announced a strategic bridge financing of up to $5 million to support Realbotix LLC during its pending acquisition. The initial advance of $2.5 million is non-interest bearing until the acquisition closes, after which it will be canceled. The acquisition is contingent on shareholder approval and regulatory conditions.
Read more →-ONCO
Sep 3, 2026▲ +9.6%on this news· ran to +51% by day 1
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events
Onconetix, Inc. has announced its acquisition of Realbotix LLC, which is launching a pilot program with a major European telecommunications company. This pilot will test the capabilities of Realbotix's humanoid robots as presenters and brand ambassadors in live events. The acquisition is expected to enhance Onconetix's offerings in innovative technology, pending necessary approvals.
Read more →-ONCO
Aug 6, 2026▼ -10.1%on this news
Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series
Onconetix, Inc. has announced that its acquisition target, Realbotix LLC, has secured an agreement to feature one of its humanoid robots in an upcoming Emmy-winning streaming series. This development showcases Realbotix's growing influence in the entertainment industry, alongside its existing applications in education, healthcare, and hospitality. The acquisition is expected to finalize in the second half of 2026, pending shareholder and regulatory approvals.
Read more →-ONCO
Aug 5, 2026▲ +20.4%on this newsshared move
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
Onconetix, Inc. announced the appointment of Ralph Schiess, PhD, to the Board of Directors of its subsidiary, Proteomedix AG. Schiess, a co-founder of Proteomedix and developer of the Proclarix® diagnostic test, brings over a decade of experience in the diagnostic industry. The appointment was made during the PMX Annual General Meeting, where Thomas Meier, PhD, was re-elected as Chairman.
Read more →-ONCO
Jul 7, 2026Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
Onconetix has highlighted a partnership between Realbotix and Bloom Services to launch a pilot program in Northeast England. The initiative will deploy humanoid robots designed to improve the wellbeing of elderly residents by providing companionship and cognitive stimulation. This program aims to supplement human caregivers and will assess its impact on loneliness and quality of life.
Read more →-ONCO
Jun 24, 2026▼ -6.5%on this news
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District
Onconetix, Inc. has highlighted Realbotix's launch of the Optio AI-powered teacher's assistant in a pilot program at Salamanca City Central School District. The initiative aims to enhance educational engagement for approximately 500 high school students by deploying both Optio and a Realbotix M-Series humanoid robot. Onconetix is also in the process of acquiring Realbotix LLC, with the transaction expected to close in the latter half of 2026.
Read more →-ONCO
May 19, 2026▼ -61.6%on this news
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
Onconetix, Inc. has announced a 1-for-10 reverse stock split effective May 21, 2026, to comply with Nasdaq's minimum bid price requirement. The decision follows stockholder approval for a reverse split ratio between 1-for-2 and 1-for-10. This move will reduce outstanding shares significantly while maintaining the same ownership percentage for shareholders.
Read more →-ONCO
May 13, 2026▼ -5.1%on this news· ran to -25% by day 3
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
Onconetix, Inc. reported significant progress in Q1 2026 through its subsidiary Proteomedix AG. The company highlighted two peer-reviewed publications that validate the effectiveness of its Proclarix® test in reducing unnecessary prostate cancer biopsies. Additionally, the PRIME study has been initiated in collaboration with Labcorp to further assess Proclarix® in the U.S. market. The company is also expanding its commercial presence in Europe.
Read more →-ONCO
Apr 9, 2026▲ +8%on this news
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson
Onconetix, Inc. announced the delivery of the first Vinci-equipped humanoid robot by Realbotix to Ericsson. Vinci, an AI vision system, enables robots to recognize users and track engagement. Onconetix is in the process of acquiring Realbotix, which is expected to enhance its offerings in innovative oncology solutions. The acquisition is pending shareholder and regulatory approvals.
Read more →-ONCO
Apr 2, 2026▼ -18.9%on this news· ran to -40% by day 3
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
Onconetix has announced its acquisition of Realbotix LLC, which is set to deliver 19 AI humanoid robots between March and May 2026. This acquisition aims to enhance Onconetix's capabilities in innovative oncology solutions. The transaction is expected to close in the second half of 2026, pending shareholder and regulatory approvals.
Read more →-ONCO
Mar 31, 2026▼ -5.1%on this news· ran to +19% by day 1shared move
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
Onconetix, Inc. has appointed David White as its new CEO and Sammy Dorf to its Board of Directors as it advances its acquisition of Realbotix LLC. David White brings over 30 years of executive experience across various sectors, indicating a potential for strong leadership. Sammy Dorf's track record in building and scaling businesses suggests he will contribute significantly to Onconetix's growth strategy. Both appointments reflect the company's commitment to creating shareholder value amid a significant acquisition.
Read more →-ONCO
Mar 25, 2026Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration
Onconetix announced its pending acquisition of Realbotix, which recently showcased its humanoid robot in Ericsson's first 6G trial. The robot served as a live endpoint, demonstrating the potential of next-gen networks for AI-driven technologies. This acquisition is anticipated to enhance Onconetix's offerings in the biotechnology sector.
Read more →-ONCO
Mar 23, 2026Onconetix, Inc. Announces 1-for-5 Reverse Stock Split
Onconetix, Inc. has announced a 1-for-5 reverse stock split effective March 25, 2026, following stockholder approval. This decision aims to ensure compliance with Nasdaq's minimum bid price requirement. The reverse split will reduce the number of outstanding shares from approximately 3.6 million to 0.7 million, while the company's stock will continue trading under the symbol 'ONCO'.
Read more →-ONCO
Feb 12, 2026▼ -42.7%on this news· ran to -59% by day 3
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company
Onconetix, Inc. has announced its acquisition of Realbotix LLC, a leader in AI-powered humanoid robotics, in an all-stock transaction. The deal, which has been unanimously approved by both companies' boards, aims to enhance Onconetix's strategic direction and shareholder value. Realbotix's technology allows its robots to operate autonomously in various public venues. The transaction is expected to close in the second half of 2026, pending regulatory approvals.
Read more →-ONCO
Sep 26, 2025▲ +6.3%on this news
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
Onconetix, Inc. has successfully completed a private placement financing of approximately $12.9 million, which will be used to settle debts and cover operational costs. The company also terminated its merger agreement with Ocuvex, Inc. and settled an $8.8 million debt with Veru, Inc. The financing includes convertible preferred stock and warrants for future stock purchases.
Read more →-ONCO
Sep 26, 2025▲ +6.3%on this newsshared move
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
Onconetix and Ocuvex have mutually terminated their merger agreement, deciding to pursue independent paths. This decision was made after careful consideration and reflects both companies' commitment to their missions. Ocuvex is preparing for the commercial launch of Omlonti, having received its New Jersey state pharmaceutical license. Both organizations expressed appreciation for the professionalism shown during the discussions.
Read more →About Onconetix, Inc.
Headquarters201 E. FIFTH STREET, CINCINNATI, OH, 45202
BIOPHARMAWATCH ELITE PLUS
Trade the next ONCO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime